Presentation of theresults of the LDOS002 clinical trial at the 9th International Conference on Contemporary Oncology.

The results of a phase I / II clinical trials with dose escalation of the L-DOS47  immunoconjugate in monotherapy of patients with non-squamous, non-small cell lung cancer (LDOS002) were presented by Prof. Cezary Szczylik at the session dedicated to personalized and precise therapy. The results suggest that the combination of L-DOS47 with drugs that work better in a neutralized microenvironment may be an effective therapy of tumors overexpressing CEACAM6.


„L-DOS47 Abstract Presentation”